Recently, the realization that non-gonadal sources of androgens, such as the adrenal glands and intra-tumoral production, might be critical in the progression of prostate cancer led to the development of abiraterone acetate, an oral specific inhibitor of CYP17A1, which is a rate-limiting enzyme in androgen (and estrogen) synthesis that, when targeted, specifically suppresses adrenal androgens [28]. This evidence concerns the gene CYP17A1 and prostate cancer.